Caldera Health intends to change the way prostate cancer is diagnosed, the way its progression is monitored, and the way its treatment is administered.
Caldera Health’s mission is to develop highly accurate prostate cancer diagnostic and prognostic tests. The tests analyse gene expression levels of selected RNA biomarkers that form gene signatures that enable diagnosis of prostate cancer and prognosis of disease progression. Our current focus is for the Caldera diagnostic test to replace the PSA test and become the new best practice in first line prostate cancer diagnostics.
About 1 in 7 men will develop prostate cancer in their lifetime. It is the second most prevalent cancer and is responsible for the fifth highest number of cancer related deaths among men worldwide. Prostate cancer is generally a slow growing cancer. If diagnosed early, the mortality rate amongst sufferers greatly reduces. However, there is currently no suitable diagnostic screening test to accurately and conveniently diagnose prostate cancer and neither is there an authoritative prognostic test that will distinguish indolent from aggressive disease.
The current first line diagnostic standard, the PSA test, analyses the amount of prostate specific antigen (PSA) in the blood. This test lacks accuracy and because of that is controversial for screening. An increase in the level of PSA in blood is not limited to prostate cancer, thus resulting in large numbers of false positive cases, requiring further unnecessary invasive procedures. This approach is at the expense of patient
well-being and cost to the bill payer. Moreover, not all prostate cancer sufferers will exhibit increased levels of PSA. This equates to missed diagnoses, which can have life threatening consequences.
Caldera Health is developing a non-invasive solution to accurately and reliably diagnose prostate cancer, thereby reducing the number of unnecessary invasive biopsies and missed diagnoses. We are developing a non-invasive urine clinical laboratory test that will measure the expression of a range of patented RNA biomarkers to precisely diagnose prostate cancer. These tests have the potential to not only identify
cancer, but also after further development, to define the progression of disease.
We plan to use the same technology platform to progress personalised medicine by determining which therapeutic approach is best for an individual patient’s cancer. By better targeting therapies to the individual cancer, both ineffective treatment and the associated time delays and costs can be greatly reduced. Caldera Health intends to change the way prostate cancer is diagnosed, the way its progression is monitored and the way its treatment is administered.